Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2016, Issue -, Pages 1-25
Publisher
Hindawi Limited
Online
2016-09-30
DOI
10.1155/2016/4757405
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery
- (2015) Chandan Verma et al. Journal of Translational Medicine
- Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival
- (2015) Jennifer Eremin et al. SpringerPlus
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Immune cell quantitation in normal breast tissue lobules with and without lobulitis
- (2014) Amy C. Degnim et al. BREAST CANCER RESEARCH AND TREATMENT
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients
- (2014) Shenyou Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line
- (2014) Faith Nutter et al. ENDOCRINE-RELATED CANCER
- CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells
- (2014) T. Yamazaki et al. JOURNAL OF IMMUNOLOGY
- The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
- (2014) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Interleukin-1 Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features
- (2013) Q. Liu et al. CANCER RESEARCH
- New Insights into the Role of the Immune Microenvironment in Breast Carcinoma
- (2013) Luis de la Cruz-Merino et al. Clinical & Developmental Immunology
- Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs
- (2013) Lutfiye Demir et al. CLINICAL & EXPERIMENTAL METASTASIS
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
- (2013) Helen Angell et al. CURRENT OPINION IN IMMUNOLOGY
- Immunotherapeutics for breast cancer
- (2013) Carmen Criscitiello et al. CURRENT OPINION IN ONCOLOGY
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- (2013) Hee Jin Lee et al. Journal of Breast Cancer
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC
- (2013) Chandan Verma et al. Journal of Translational Medicine
- The Tumor Microenvironment: A Pitch for Multiple Players
- (2013) Giovanna Schiavoni et al. Frontiers in Oncology
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+tumor infiltrating lymphocytes in ductal and lobular breast cancers
- (2012) Raoul Droeser et al. BMC CANCER
- Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer
- (2012) Steven D. Heys et al. BREAST CANCER RESEARCH AND TREATMENT
- Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients
- (2012) Fangfang Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients
- (2012) Naofumi Oda et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
- (2012) N R West et al. BRITISH JOURNAL OF CANCER
- Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
- (2012) D. T. Le et al. CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
- (2012) Abhishek D Garg et al. EMBO JOURNAL
- Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer
- (2012) Rin Yamaguchi et al. HUMAN PATHOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- PD1 makes waves in anticancer immunotherapy
- (2012) Alexandra Flemming NATURE REVIEWS DRUG DISCOVERY
- Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
- (2012) L. Menger et al. Science Translational Medicine
- Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
- (2011) Leslie G Walker et al. BMC CANCER
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunological monitoring of the tumor immunoenvironment for clinical trials
- (2011) Anatoli M. Malyguine et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
- (2011) Sylvain Ladoire et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
- (2011) S. R. Mattarollo et al. CANCER RESEARCH
- Immunoregulatory Molecule B7-H1 (CD274) Contributes to Skin Carcinogenesis
- (2011) Y. Cao et al. CANCER RESEARCH
- Th17 cells in cancer: help or hindrance?
- (2011) Cailin Moira Wilke et al. CARCINOGENESIS
- Expression of Th17 Cells in Breast Cancer Tissue and Its Association with Clinical Parameters
- (2011) LiJuan Yang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- CD8+Foxp3+ T cells share developmental and phenotypic features with classical CD4+Foxp3+ regulatory T cells but lack potent suppressive activity
- (2011) Christian T. Mayer et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
- (2011) Genevieve M. Weir et al. Cancers
- Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy
- (2010) Sylvain Ladoire et al. BREAST CANCER RESEARCH AND TREATMENT
- An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
- (2010) Sahar M. A. Mahmoud et al. BREAST CANCER RESEARCH AND TREATMENT
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization
- (2010) Christine M. Barbon et al. CELLULAR IMMUNOLOGY
- New Insights of CTLA-4 into Its Biological Function in Breast Cancer
- (2010) H. Mao et al. CURRENT CANCER DRUG TARGETS
- Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
- (2010) Fabrice Andre et al. CURRENT OPINION IN ONCOLOGY
- Regulatory T cells in tumor immunity
- (2010) Hiroyoshi Nishikawa et al. INTERNATIONAL JOURNAL OF CANCER
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
- (2009) M. Gobert et al. CANCER RESEARCH
- Transforming growth factor beta (TGF-β) and inflammation in cancer
- (2009) Brian Bierie et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Global Mapping of H3K4me3 and H3K27me3 Reveals Specificity and Plasticity in Lineage Fate Determination of Differentiating CD4+ T Cells
- (2009) Gang Wei et al. IMMUNITY
- Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
- (2009) Ethan M. Shevach IMMUNITY
- Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB
- (2009) Jae Yeo Park et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- FOXP3 Expression and Overall Survival in Breast Cancer
- (2009) Andrea Merlo et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- STAT6 Activation Confers upon T Helper Cells Resistance to Suppression by Regulatory T Cells
- (2009) B. B. L. Pillemer et al. JOURNAL OF IMMUNOLOGY
- Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer
- (2008) Ninke Leffers et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
- (2008) S. Ladoire et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started